| P2093 | author name string | I Behrmann | |
| | J Kaczor | |
| | S Haan | |
| | S Wüller | |
| | C Haan | |
| | C Rolvering | |
| | T Nöcker | |
| P2860 | cites work | A family of cytokine-inducible inhibitors of signalling | Q24313168 |
| | A new protein containing an SH2 domain that inhibits JAK kinases | Q24313242 |
| | The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop | Q24533774 |
| | Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. | Q24537294 |
| | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 |
| | CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2 | Q28140132 |
| | Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain | Q28140535 |
| | SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 | Q28201656 |
| | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
| | Structure and function of a new STAT-induced STAT inhibitor | Q28584775 |
| | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 |
| | JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 |
| | Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation | Q33559005 |
| | Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 |
| | Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | Q34245259 |
| | JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model | Q35849213 |
| | Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 |
| | Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia | Q36275870 |
| | SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome | Q37527082 |
| | Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders | Q38437889 |
| | The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera | Q38439703 |
| | Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders | Q38473283 |
| | Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. | Q40031223 |
| | Characterization of murine JAK2V617F-positive myeloproliferative disease | Q40200859 |
| | Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells | Q40235023 |
| | Activated Jak2 with the V617F point mutation promotes G1/S phase transition | Q40288678 |
| | JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders | Q40330808 |
| | Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein | Q40351672 |
| | Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line | Q40486172 |
| | Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase | Q40559879 |
| | The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. | Q40816941 |
| | Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. | Q40889649 |
| | Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. | Q43031345 |
| | STAT3 is constitutively active in some patients with Polycythemia rubra vera | Q43621409 |
| | SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma | Q44232582 |
| | Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases | Q46486264 |
| | Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders | Q46719544 |
| | Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice | Q46832173 |
| | A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. | Q52993336 |
| | Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. | Q53663088 |
| | The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 | Q58483483 |
| | Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia | Q60171394 |
| | The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders | Q79214771 |
| | Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia | Q80886068 |
| | Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia | Q81600825 |
| | Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells | Q83310312 |
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3069-3080 | |
| P577 | publication date | 2009-06-22 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling | |
| P478 | volume | 28 | |